热门资讯> 正文
Valneva 2025年初步收入为1.747亿欧元，高于2024年的1.696亿欧元，现金为1.097亿欧元; 2026年指南总收入为1.55亿欧元-1.7亿欧元，产品销售额为1.45亿欧元-1.6亿欧元，预计2026年上半年有3期莱姆病数据
2026-02-19 14:44
- Total Revenues of €174.7 million in line with guidance, including €157.9 million in product sales
- Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing
- 2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the year
- Chief Executive Officer's contract renewed for a further three-year term, ensuring continuity in leadership
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
